CCL3 and B-cell chronic lymphocytic leukemia: Similar with Ibrutinib, Acalabrutinib treatment inhibits the migratory capacity of CLL cells mediated by tissue-homing chemokines, CCL3 and CCL4 [14, 15], and induces CLL-cell apoptosis accompanied by cleavage of PARP and caspase-3 via inhibiting the activation of ERK and AKT [16].